tag:blogger.com,1999:blog-7857054149675424609.post2235440708878618518..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Targeted Delivery Strategies Coming to the ForeDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-7857054149675424609.post-16538089431180917292010-04-02T15:06:29.421+00:002010-04-02T15:06:29.421+00:00I have tried to distill some of the rationale behi...I have tried to distill some of the rationale behind the 'takeover' of Cequent in my post today (April 2, 2010). It is probably best to search the entire blog content for my views on the technologies involved. tkRNAi does not compete at all with liposomal delivery such as practiced by Tekmira or (former) mdRNA as they target quite different therapeutic applications, except if you considerDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-72051371932871805102010-04-01T19:54:47.834+00:002010-04-01T19:54:47.834+00:00Dirk:
Given your relationship with Cequent and t...Dirk:<br /> Given your relationship with Cequent and today's news. Could you talk about their technology (ceq-508, etc...) and how it differs better or worse than say for ex.Tekmira's? Given the run rate of the combined co. is it accurate that they only have enough $$ to last until 12/10??? What are your thoughts on the new MRNA regarding tech.,products and funding needs and how NVS Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-11101456206948113372010-03-31T14:27:46.070+00:002010-03-31T14:27:46.070+00:00In the event that the decision is eventually uphel...In the event that the decision is eventually upheld, I would imagine that small RNA diagnostic companies would only develop tests for indications with very large populations of potential patients where it would still be profitable despite competition. Small niche indications might be neglected. At least all diagnostic companies would be in the same boat. <br /><br />They might also decide to Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-53571173952649064222010-03-31T05:56:21.972+00:002010-03-31T05:56:21.972+00:00Dr. Haussecker,
This is David Germain, an MD/PhD ...Dr. Haussecker,<br /><br />This is David Germain, an MD/PhD student at Washington University in St. Louis (and former Stanford undergrad - Go Card!). I was hoping to ask your opinion on a few issues regarding RNAi patent coverage. I also had a few questions about the RNAi therapeutic companies you discuss in your blog.<br /><br />If you could contact me (e-mail or Gchat) at dgermain21@gmail.com Unknownhttps://www.blogger.com/profile/03215417736830730454noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-26292546501366897472010-03-30T19:56:03.596+00:002010-03-30T19:56:03.596+00:00My ad hoc assessment on the Myriad ruling, if it w...My ad hoc assessment on the Myriad ruling, if it will indeed hold up and ripple through biotech IP, is that it will have its most significant effects on the ability to claim a given gene as a target for RNA(i) therapeutic, especially if the basis is a mere brute-force blanketing of a gene with a battery of siRNAs as Sirna Therapeutics once did, and mdRNA aimed to replicate. In a way one could Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-88132307004298896602010-03-30T14:17:49.491+00:002010-03-30T14:17:49.491+00:00What effect will yesterday's ruling that some ...What effect will yesterday's ruling that some of Myriad Genetic's patents are not valid have on companies in the RNAi space?<br /><br />Does it level the playing field and actually help some companies?<br /><br />Will it have little effect since patents can be designed around anyway?Anonymousnoreply@blogger.com